REDWOOD CITY, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Cardica, Inc. (Nasdaq:CRDC) today announced that Julian Nikolchev, the company’s president and CEO, with give a corporate overview and update at Source Capital’s 2016 Disruptive Growth and Healthcare Conference on Wednesday, February 10, 2016 at 4:00pm Eastern Time in New York City.
For more information on the conference, or for investor registration, please go to www.SourceCapitalConference.com. To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company's website at http://www.cardica.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.
About Source Capital Group
Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com/
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and minimally invasive surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally invasive and robot-assisted surgeries. Cardica’s MicroCutter XCHANGE® 30, that includes a cartridge-based articulating surgical stapling device with a five-millimeter shaft diameter and staples, is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine and the transection of the appendix. The MicroCutter XCHANGE 30 white cartridge staple has application in vascular tissue. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 57,500 units throughout the world.
Contact: Bob Newell Vice President, Finance and Chief Financial Officer (650) 331-7133 email@example.com